Tesaro Inc. (NASDAQ:TSRO) – Equities researchers at Leerink Swann lifted their FY2020 EPS estimates for Tesaro in a note issued to investors on Sunday. Leerink Swann analyst S. Fernandez now forecasts that the firm will post earnings per share of $9.47 for the year, up from their previous estimate of $8.88. Leerink Swann has a “Outperform” rating and a $115.00 price target on the stock.

Tesaro (NASDAQ:TSRO) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.71) by $0.43. Tesaro had a negative net margin of 783.97% and a negative return on equity of 205.63%. The business had revenue of $36.60 million for the quarter, compared to analyst estimates of $4.98 million. During the same period in the prior year, the company posted ($1.51) EPS.

Earnings History and Estimates for Tesaro (NASDAQ:TSRO)

A number of other brokerages have also weighed in on TSRO. Mizuho restated an “outperform” rating and issued a $67.00 price objective on shares of Tesaro in a report on Thursday, June 30th. Lake Street Capital reiterated a “buy” rating and set a $114.00 price target on shares of Tesaro in a research note on Tuesday, September 6th. Robert W. Baird lifted their price target on shares of Tesaro from $105.00 to $120.00 and gave the stock an “outperform” rating in a research note on Monday. FBR & Co reiterated a “buy” rating on shares of Tesaro in a research note on Thursday, June 30th. Finally, Wells Fargo & Co. reiterated an “outperform” rating on shares of Tesaro in a research note on Thursday, June 30th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and thirteen have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $110.11.

Tesaro (NASDAQ:TSRO) traded down 0.49% during midday trading on Tuesday, hitting $114.77. 1,159,702 shares of the stock traded hands. The company’s 50 day moving average is $97.53 and its 200-day moving average is $70.11. Tesaro has a one year low of $29.51 and a one year high of $122.89. The company’s market cap is $5.90 billion.

In related news, VP Jeffrey H. Hanke sold 29,166 shares of the business’s stock in a transaction dated Tuesday, August 30th. The shares were sold at an average price of $86.04, for a total transaction of $2,509,442.64. Following the sale, the vice president now owns 29,166 shares of the company’s stock, valued at $2,509,442.64. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Martin H. Jr. Huber sold 408 shares of the business’s stock in a transaction dated Thursday, September 22nd. The stock was sold at an average price of $108.12, for a total transaction of $44,112.96. Following the sale, the senior vice president now directly owns 1,250 shares in the company, valued at approximately $135,150. The disclosure for this sale can be found here. Corporate insiders own 40.50% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. increased its stake in Tesaro by 13.3% in the first quarter. BlackRock Inc. now owns 7,096 shares of the biopharmaceutical company’s stock worth $312,000 after buying an additional 834 shares in the last quarter. BlackRock Group LTD increased its stake in Tesaro by 7.9% in the first quarter. BlackRock Group LTD now owns 162,499 shares of the biopharmaceutical company’s stock worth $7,154,000 after buying an additional 11,880 shares in the last quarter. BlackRock Fund Advisors increased its stake in Tesaro by 1.8% in the first quarter. BlackRock Fund Advisors now owns 1,293,906 shares of the biopharmaceutical company’s stock worth $56,971,000 after buying an additional 23,384 shares in the last quarter. State Street Corp increased its stake in Tesaro by 0.7% in the first quarter. State Street Corp now owns 893,749 shares of the biopharmaceutical company’s stock worth $39,349,000 after buying an additional 6,026 shares in the last quarter. Finally, Pictet Asset Management Ltd. increased its stake in Tesaro by 35.8% in the first quarter. Pictet Asset Management Ltd. now owns 55,000 shares of the biopharmaceutical company’s stock worth $2,225,000 after buying an additional 14,500 shares in the last quarter. 88.81% of the stock is currently owned by hedge funds and other institutional investors.

Tesaro Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.

5 Day Chart for NASDAQ:TSRO

Receive News & Stock Ratings for Tesaro Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tesaro Inc. and related stocks with our FREE daily email newsletter.